← Back to patent-cliff list
CAS 415697-56-2
N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
Codes: SPAR-013
Application context (from source-drug indications)
局灶性节段性肾小球硬化症Sparsentan免疫球蛋白a肾病Sparsentan抗中性粒细胞胞浆抗体相关性血管炎SparsentanKidney diseaseSparsentanAlport 综合征Sparsentan过敏性紫癜Sparsentan
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Sparsentan | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 4-bromo-3-(ethoxymethyl)benzoate→2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one→(4-bromo-3-(ethoxymethyl)phenyl)methanol→4-bromo-3-(ethoxymethyl)benzyl methanesulfonate→3-(4-bromo-3-(ethoxymethyl)benzyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one dioxalate→N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
Intermediates available on this site
Side-by-side comparison of all listed offers on this CAS; price bands are list-price ranges, final price subject to RFQ confirmation.
| Supplier | Product | Price band | MOQ | Lead time | Qualifications | Action |
|---|---|---|---|---|---|---|
| Unibest Nantong cGMP Site | N-(4,5-dimethylisoxazol-3-yl)-N-(methoxymethyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Pharmaceutical Intermediates | On request | On request | On request | — |
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.